BioSpace News Archive

Job Trends

Top 5 Remote Regulatory Jobs

Looking for remote regulatory jobs in the life sciences industry? Check out the BioSpace list of the top five jobs that don’t require relocation.

April 24, 2024
·
1 min read
·
Angela Gabriel
Business

Roche Trims Four Early Assets as Q1 Sales Slip 6% on Currency, COVID Headwinds

Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.

April 24, 2024
·
2 min read
·
Tristan Manalac
Business

Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas

The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the future of stem cell therapies to fight autoimmune disease, cancer, even aging.

April 24, 2024
·
5 min read
·
Neil Versel
Business

A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach

Takeda Oncology US Head of Sales, Annette Montandon, discusses how embodying a patient-first approach is key to the success of colorectal cancer drug FRUZAQLA®.

April 24, 2024
·
4 min read
·
BioSpace Insights
DEI

Where Do We Go From Here? The Future of Women’s Health

In the second episode of our series on women’s health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories.

April 24, 2024
·
1 min read
·
Lori Ellis
Career Advice

7 Types of Difficult Bosses and How to Deal With Them

By understanding the different types of difficult bosses, you can shift your perspective and approach the situation from a less stressful, more effective angle.

April 24, 2024
·
5 min read
·
Angela Gabriel
Policy

FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier

The FTC’s final rule banning most new noncompetes should go into effect later this year, although it faces opposition from the U.S. Chamber of Commerce.

April 24, 2024
·
5 min read
·
Angela Gabriel
FDA

Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.

April 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study

An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.

April 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Endeavor Raises $132M in Oversubscribed Series C to Advance Lung Disease, ADC Candidates

While the San Diego-based biotech awaits a Phase IIa data readout for its lead lung disease candidate, Endeavor BioMedicines’ next-generation HER3-targeted antibody-drug conjugate will start a Phase I/II trial later this year.

April 24, 2024
·
2 min read
·
Tyler Patchen